Revisiting the Electrophysiology of Ventricular Myocardium

For several decades, cardiac electrophysiologists classified the ultrarapid delayed rectifier potassium current (IKur) as a strictly atrial-specific ion current. Consequently, most clinical models focused on its role in atrial fibrillation while ignoring its potential influence on the lower chambers. However, recent research has fundamentally challenged this long-standing paradigm. A comprehensive study using both canine and human cardiac tissues now confirms that IKur is functionally active within the ventricular myocardium. This discovery is pivotal because it highlights a previously unrecognized contributor to the ventricular repolarization reserve. By understanding this current, clinicians can better appreciate how the heart maintains electrical stability under physiological stress. Furthermore, these findings suggest that the ventricles possess more complex repolarization mechanisms than previously assumed. Therefore, the traditional view of chamber-specific ion currents requires a significant update to reflect these molecular realities. Specifically, the presence of Kv1.5 protein, which conducts the IKur current, has been verified across various ventricular cell types. This shift in understanding opens new avenues for exploring ventricular arrhythmias and therapeutic interventions. Ultimately, acknowledging the role of IKur in the ventricles enhances our comprehension of cardiac safety and drug-induced electrical instability.

Molecular Evidence of Kv1.5 Expression in Ventricles

The study employed advanced immunocytochemistry and molecular techniques to locate Kv1.5 protein expression in undiseased human and canine hearts. Researchers detected these proteins not only in the expected atrial tissues but also within the left ventricular myocardium and Purkinje fibers. Notably, the expression levels in canine ventricular myocytes were comparable to those found in atrial cells. This evidence directly contradicts the theory that IKur is absent in the ventricles. Additionally, the researchers utilized whole-cell patch-clamp techniques to measure the actual ionic currents in isolated cardiomyocytes. These measurements confirmed that the ionic current attributed to IKur is indeed functionally active and measurable. Moreover, the magnitude of these currents in ventricular myocytes suggests they are not merely vestigial remnants. Instead, they appear to be integral components of the myocyte's electrical repertoire. Consequently, the molecular architecture of the ventricular wall is more similar to the atria than once believed regarding potassium channel distribution. Thus, the identification of Kv1.5 in ventricular tissue provides a robust physical basis for the observed electrophysiological effects. This molecular verification is the first step in redefining the functional landscape of ventricular repolarization.

Impact on Action Potential and Functional Activity

When researchers applied 4-aminopyridine (4-AP) to inhibit the IKur current, they observed distinct changes in the action potential (AP) morphology of ventricular preparations. In canine models, inhibiting IKur caused a significant prolongation of the action potential duration (APD) in endocardial and midmyocardial tissues. Furthermore, Purkinje fibers also showed a marked sensitivity to IKur inhibition, leading to delayed repolarization. These functional changes indicate that IKur actively assists in the timely recovery of the cardiac membrane potential. In addition to experimental tissue recordings, in silico simulations using the T-World human ventricular model supported these findings. The computational data demonstrated that the IKur current contributes to the plateau phase of the ventricular action potential. Therefore, its absence or inhibition directly impacts the rate at which the cell returns to its resting state. Interestingly, while the current's magnitude is modest compared to other potassium currents, its functional influence is substantial. Consequently, IKur serves as a critical stabilizing force during the delicate repolarization process. By modulating the AP duration, this current helps ensure that the heart remains ready for subsequent electrical impulses without delay.

Strengthening the Ventricular Repolarization Reserve

The concept of the ventricular repolarization reserve is central to understanding why some patients develop arrhythmias while others remain stable. This reserve acts as a redundancy system where multiple ion currents, such as IKr, IKs, and now IKur, work together to ensure successful repolarization. If one current is weakened by genetic defects or drugs, the others must compensate to prevent excessive APD prolongation. The study demonstrates that IKur represents a significant portion of this compensatory capacity. Specifically, under conditions where the repolarization reserve was already attenuated, the inhibition of IKur led to dramatic electrical instability. This suggests that IKur becomes increasingly important when the heart's primary repolarization pathways are compromised. Moreover, the ability of IKur to provide this backup support makes it a vital protector against sudden cardiac death. Therefore, the total repolarization capacity of the ventricle is the sum of these integrated ionic currents. Thus, clinicians must consider the cumulative effect of various channel blockers on this reserve. Protecting this reserve is paramount for maintaining a stable sinus rhythm and preventing the dangerous lengthening of the QT interval.

Clinical Consequences of IKur Inhibition and EADs

A major finding of the research was the link between IKur inhibition and the formation of early afterdepolarizations (EADs). EADs are abnormal electrical oscillations that occur during the repolarization phase and often trigger lethal ventricular arrhythmias like Torsades de Pointes. When the researchers blocked IKur in hearts with a reduced ventricular repolarization reserve, EADs occurred frequently. This indicates that IKur plays a defensive role in preventing the membrane potential from hovering in a dangerously unstable state. Furthermore, the in silico models accurately predicted these EAD formations, validating the experimental results. Consequently, drugs that unintentionally block IKur might carry a higher pro-arrhythmic risk than previously estimated, particularly in vulnerable patients. Additionally, patients with existing heart disease or those taking multiple medications may have a fragile repolarization reserve that relies heavily on IKur. Therefore, the safety profiles of many pharmacological agents may need re-evaluation in light of these ventricular effects. Identifying patients with diminished reserve could help prevent drug-induced cardiac events. Ultimately, this research emphasizes the need for a more holistic view of cardiac ion channel pharmacology.

Future Directions in Anti-Arrhythmic Research

The discovery of IKur's role in the ventricles has significant implications for future drug development and arrhythmia management. Previously, drug developers sought atrial-selective IKur blockers to treat atrial fibrillation with minimal ventricular side effects. However, these new findings suggest that blocking IKur may not be entirely "ventricular-safe," especially in patients with low repolarization reserves. Conversely, enhancing IKur activity could theoretically provide a new therapeutic strategy to strengthen the repolarization reserve in high-risk individuals. Furthermore, this research highlights the necessity of using more accurate human-based models in safety pharmacology. Since canine and human tissues showed similar IKur involvement, both remain valuable for studying these complex interactions. Moreover, future studies should investigate how common diseases like heart failure or hypertension affect ventricular IKur expression. If these conditions downregulate IKur, they could further predispose the heart to electrical failure. Thus, the clinical community must stay informed about these evolving concepts in cardiac electrophysiology. Continued exploration of the ventricular repolarization reserve will lead to safer pharmacological practices and better patient outcomes. Therefore, the scientific journey to map every current within the human heart continues to provide essential insights for modern medicine.

Frequently Asked Questions

How does IKur contribute to the ventricular repolarization reserve?

The ultrarapid delayed rectifier potassium current, or IKur, acts as a critical component of the heart's electrical redundancy system. It provides an outward flow of potassium ions during the plateau phase of the ventricular action potential. By contributing to this total outward current, IKur helps ensure that the cell returns to its resting state efficiently. Even when other currents like IKr or IKs are impaired, IKur provides the necessary electrical force to prevent dangerous delays in repolarization.

Can IKur inhibition lead to dangerous ventricular arrhythmias?

Yes, IKur inhibition can potentially lead to arrhythmias, particularly when the heart's overall repolarization reserve is already weakened. When IKur is blocked, the action potential duration lengthens significantly. This delay creates a window of vulnerability where early afterdepolarizations (EADs) can occur. These EADs are known triggers for life-threatening conditions such as Torsades de Pointes. Therefore, maintaining functional IKur is essential for preventing electrical instability in the ventricular myocardium and Purkinje fibers.

Why was IKur previously thought to be absent in the ventricles?

Historically, early electrophysiological studies focused on the high density of IKur in the atria, leading to the conclusion that it was chamber-specific. Technological limitations and differences in animal models also contributed to this misconception. Because other potassium currents are more dominant in the ventricles, the relatively smaller contribution of IKur was often overlooked or dismissed as noise. However, improved molecular detection and high-resolution patch-clamp techniques have finally confirmed its presence and functional activity in human and canine ventricular tissues.

Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Abdelmagid AAE et al. The ultrarapid delayed rectifier potassium current has important functional role in the repolarization reserve of canine and human ventricular muscle. J Physiol. 2026 Jun 27. doi: 10.1113/JP290706. PMID: 42365398.

Schmitt N, Grunnet M, Olesen SP. Cardiac potassium channels: an update. Cardiovasc Res. 2014;103(4):443-452. doi:10.1093/cvr/cvu129.

Ravens U, Wettwer E. Ultra-rapid delayed rectifier channels: molecular identity and functions. Cardiovasc Res. 2011;89(4):776-785. doi:10.1093/cvr/cvq350.